USA – Sema4 has announced an agreement to acquire OPKO Health’s genomic testing and analysis subsidiary GeneDx, creating “one of the largest” providers of genomic clinical testing in the United…
Read MoreDay: 20 January 2022
Iterative Scopes bags US$150M in funding to enhance AI for gastroenterology
USA – Iterative Scopes announced it has raised US$150 million in Series B funding round on to accelerate the development of its core algorithmic innovations for gastrointestinal (GI) disease care.…
Read MorePhilips partners Cydar to improve Zenition mobile C-arm system
NETHERLANDS – Philips has announced that it has integrated advanced new 3D image guidance capabilities into its Zenition image-guided therapy mobile C-arm system through a collaboration with Cydar. The agreement…
Read MoreHal Barron to swap GSK for anti-ageing start-up Altos Labs
UNITED KINGDOM – GlaxoSmithKline announced on Wednesday that Hal Barron, chief scientific officer (CSO), will leave the company later this year to become CEO of the biotechnology start-up Altos Labs.…
Read MoreUnilever backs down on US$68.3 billion bid for GSK’s consumer health arm
UNITED KINGDOM – Unilever has ruled out increasing its £50 billion (US$68.3 billion) bid for GlaxoSmithKline’s consumer health unit after the pharma giant turned down the latest of three approaches…
Read MoreUCB to acquire Zogenix in US$1.9 billion deal
BELGIUM – Belgian-based UCB has agreed to buy Zogenix Inc, a U.S. maker of drugs to treat seizures and rare diseases, for US$1.9 billion, expanding its portfolio to treat epilepsy.…
Read MoreMyHealthcare appoints Sanjay Bapna as Chief Commercial Officer
INDIA – MyHealthcare, a pioneer in the digital healthcare ecosystem, has announced the appointment of Sanjay Bapna as Chief Commercial Officer. MyHealthcare is a specialized healthcare platform that collaborates with…
Read MoreRoche to reexamine Huntington’s disease drug
SWITZERLAND – Roche has outlined a new clinical path forward for tominersen, a closely watched Huntington’s disease drug, ten months after disappointing Phase 3 study results appeared to spell the…
Read More